Adial Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds

Under the collaboration agreement, Dr. Ernst and his team will initially test Purnovate’s adenosine compounds in non-clinical models of IBD with the goal of further validating the potential of Purnovate’s compounds as a treatment for IBD. Dr. Ernst stated, “Based on experience, I am keen to see whether these adenosine analogs can effectively address the historical challenges of solubility and biodistribution. My team looks forward to evaluating the compounds for their potential therapeutic benefit to patients suffering from inflammatory bowel disease and other inflammatory conditions.”